Galapagos NV (Amsterdam) 

(Public, AMS:GLPGA)   Watch this stock   
Find more results for GLPGA

Key stats and ratios

Q2 (Jun '09) 2008
Net profit margin -19.38% -18.95%
Operating margin -23.69% -19.77%
EBITD margin - -10.20%
Return on average assets -12.94% -10.90%
Return on average equity -17.80% -15.94%
Employees 482 -

Address

Industriepark Mechelen Noord Generaal De Wittelaan L11 A3
Mechelen, 2800
Belgium
+32-15-342900 (Phone)
+32-15-342901 (Fax)

Website links

Galapagos NV (Amsterdam) discussions

  View all discussions »

Description

Galapagos NV is a Belgium-based biotechnology company. The Company is divided into two operating divisions: Drug Discovery and BioFocus DPI. The Drug Discovery division has programs in bone and joint diseases, including osteoarthritis, osteoporosis and rheumatoid arthritis. The BioFocus DPI service division offers a suite of target-to-drug discovery products and services to pharmaceutical and biotechnology companies, encompassing target discovery and drug discovery services through to delivery of pre-clinical candidates. The Company also forms strategic long-term alliances for the majority of its research programs with large pharmaceutical companies. Galapagos NV's operations are located in Belgium, France, Switzerland, the Netherlands, the United Kingdom and the United States.

Officers and directors

Onno Van de Stolpe
Chief Executive Officer, Executive Director
Age: 50
Guillaume Jetten
Chief Financial Officer
Age: 41
Graham Dixon
Senior Vice President - Drug Discovery
Andre Hoekema
Senior Vice President - Corporate Development
Christopher Newton
Senior Vice President - BioFocus DPI
Piet Wigerinck
Senior Vice President - Development
Raj Parekh
Non-Executive Chairman of the Board
Age: 49
Harrold Van Barlingen
Non-Executive Director
Age: 44
Werner Cautreels
Independent Director
Age: 56
Ferdinand L.J. Verdonck
Non-Executive Independent Director
Age: 66